Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mexico’s Health Care Agency Alleges Zimmer Fraud

Executive Summary

Mexico’s health care agency is suing Zimmer Biomet for a refund on purchases it made from the company during a long-running bribery scheme. The agency claims the bribery, which was admitted in a 2017 settlement with the US government, nullified its contracts with the device maker.

You may also be interested in...



Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger

Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.

Zimmer Biomet To Settle Overseas Bribery Charges With US DOJ

The orthopedic device company is set to pay $17.4m to the US Department of Justice and an additional $13m to the Securities and Exchange Commission to resolve allegations that Biomet didn’t stop corrupt acts in Brazil and Mexico even after a 2012 deferred prosecution agreement.

Zimmer, Biomet Sell Off Some U.S. Assets As They Finalize A $14 Bil. Merger

Zimmer Biomet is now the second-largest orthopedic device maker behind Johnson & Johnson now that the merger between the two firms is complete. The companies divested some U.S. knee, elbow and bone cement assets in conjunction with finalized the deal after having sold of some European assets earlier in the year.

Topics

Related Companies

UsernamePublicRestriction

Register

MT126217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel